Tocilizumab, a novel monoclonal antibody targeting IL-6 signalling, significantly reduces disease activity in patients with rheumatoid arthritis

被引：0
|
作者：
Smolen, J. [1 ]
Beaulieu, A. [2 ]
Rubbert-Roth, A. [3 ]
Alecock, E. [4 ]
Alten, R. [5 ]
Woodworth, T. [4 ]
机构：
[1] Univ Clin Internal Med, Clin Dept Pheumatol, Vienna, Austria
[2] Univ Laval, Fac Med, Quebec City, PQ G1K 7P4, Canada
[3] Univ Cologne, Med Clin 1, Cologne, Germany
[4] Roche Prod Ltd, Welwyn, SK, Canada
[5] Charite Univ Med Berlin, Schlosspk Clin, Dept Internal Med 2, D-13353 Berlin, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：87 / 88
页数：2
相关论文
共 50 条
  • [21] Serum Levels of IL-17, IL-6, TNF-α and Disease Activity in Patients with Rheumatoid Arthritis
    Beyazal, M. S.
    Devrimsel, G.
    Cure, M. C.
    Turkyilmaz, A. K.
    Capkin, E.
    Karkucak, M.
    AKTUELLE RHEUMATOLOGIE, 2017, 42 (04) : 323 - 328
  • [22] CHANGES OF ADIPOKINE SERUM LEVELS AFTER IL-6 RECEPTOR BLOCKADE WITH TOCILIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Fragiadaki, K.
    Makrilakis, K.
    Smith, J.
    Sfikakis, P. P.
    Kitas, G. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 884 - 884
  • [23] IL-6 promoter polymorphism in patients with rheumatoid arthritis
    Pawlik, A
    Wrzesniewska, J
    Florczak, M
    Gawronska-Szklarz, B
    Herczynska, M
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2005, 34 (02) : 109 - 113
  • [24] CORRELATION BETWEEN IL-6 AND OSTEOCALCIN SERUM LEVELS WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Rapushi, Ervin
    Backa, Teuta
    Zoto, Artur
    Zicishti, Ermira
    Nuhaj, Lediana
    Salko, Valbona
    Xhemali, Indin
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 292 - 292
  • [25] New in the therapy of rheumatoid arthritis Inhibition of interleukin-6-receptor with tocilizumab reduces the disease activity
    Blank, Norbert
    MEDIZINISCHE KLINIK, 2009, 104 (05) : 401 - 402
  • [26] Increase in serum levels of IL-6 and soluble IL-6 receptor after anti-IL-6 receptor antibody therapy in patients with rheumatoid arthritis
    Nishimoto, N
    Terao, K
    Kakehi, T
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S109 - S110
  • [27] Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL-6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
    Diaz-Torne, Cesar
    Jose De Agustin, Juan
    Moya, Patricia
    Ortiz, Maria A.
    Reina, Delia
    Moragues, Carme
    Ros, Sergi
    Gomez, Emili
    Casado Burgos, Enrique
    Garcia, Eli
    Pujol, Manel
    Lisbona Perez, Maria Pilar
    Ponce, Andres
    Torrente, V.
    Estrada, P.
    Vidal, Silvia
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [28] Tocilizumab: a novel humanized anti-interleukin 6 receptor antibody for the treatment of patients with rheumatoid arthritis
    Alten, Rieke
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (03) : 133 - 149
  • [29] BLOCKING INTERLEUKIN-6 (IL-6) BY AN ANTI-INTERLEUKIN-6 RECEPTOR (IL-6R) MONOCLONAL ANTIBODY IN RHEUMATOID ARTHRITIS (RA)
    Choy, E. H. S.
    Isenberg, D. A.
    Garrood, T.
    Farrow, S.
    Ioannou, Y.
    Bird, H.
    Cheung, N.
    Williams, B. D.
    Hazleman, B.
    Price, R.
    Kishimoto, T.
    Panayi, G. S.
    RHEUMATOLOGY, 2002, 41 : 15 - 15
  • [30] TOCILIZUMAB STANDARD DOSE IS AN OVERTREATMENT WITH REGARD TO SYSTEMIC IL-6 RECEPTOR BLOCKADE IN RHEUMATOID ARTHRITIS
    Kneepkens, E. L.
    van den Oever, I. A.
    Plasencia, C. H.
    Pascual-Salcedo, D.
    van der Kleij, D.
    Hart, M.
    Nurmohamed, M. T.
    Balsa, A.
    Aarden, L.
    Rispens, T.
    Wolbink, G. J.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 723 - 723
12345